FIELD: medicine, pharmacy.
SUBSTANCE: invention relates to a pharmaceutical composition for oral administration in treatment or prophylaxis of obesity or hyperlipidemia. The composition comprises orlistat and at least one ester of fatty acids and polyols. Melting point of fatty acid ester exceeds the body temperature and polyol is taken among group including glycerol, sugars, derivatives of sugars and their mixtures. Also, invention relates to a method for preparing above described composition and to a method for treatment or prophylaxis of obesity. Invention enhances effectiveness and activity of orlistat by reducing variability of effectiveness and/or activity of orlistat between patients and frequency and severity of adverse effects.
EFFECT: improved and valuable pharmaceutical properties of compositions.
24 cl, 1 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DISPERSION COMPOSITION CONTAINING LIPASE INHIBITORS | 2000 |
|
RU2239428C2 |
| PHARMACEUTICAL COMPOSITION COMPRISING LIPASE INHIBITOR AND SUCROSE FATTY ACID ESTER | 2002 |
|
RU2271808C2 |
| NOVEL PHARMACEUTICAL COMPOSITION | 2001 |
|
RU2241462C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING LIPASE INHIBITOR AND GLUCOMANNAN | 2003 |
|
RU2297221C2 |
| METHOD FOR PREPARING COMPOSITION | 2001 |
|
RU2244542C2 |
| DERIVATIVES OF OXAZOLE AND THEIR USING AS INSULIN SENSITIZING AGENTS, PHARMACEUTICAL COMPOSITION POSSESSING ACTIVATING EFFECT ON PPARα AND/OR PPARγ | 2003 |
|
RU2295520C2 |
| PHARMACEUTICAL COMPOSITION HAVING ANTI-OBESITY ACTIVITY CONTAINING THE PREMIX OF PURE ORLISTAT AND THE WAY OF ITS MANUFACTURING | 2010 |
|
RU2441654C2 |
| PHARMACEUTIC COMPOSITION, BIOLOGICALLY ACTIVE ADDITIVE AND METHOD OF REDUCING FAT ABSORPTION FROM FOOD | 2009 |
|
RU2412713C2 |
| N-SUBSTITUTED 1H-INDOLE-5-PROPIONIC ACIDS, PHARMACEUTICAL COMPOSITION CONTAINING THESE COMPOUNDS AND THEIR USING (VARIANTS) | 2003 |
|
RU2296759C2 |
| DERIVATIVES OF 1,1-DIOXOTHIOMORPHOLINYLINDOLYL METHANONE FOR USE AS HISTAMINASE MODULATORS | 2006 |
|
RU2412182C2 |
